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Abstract
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cornerstone in
treatment of hematological malignancies. However, relapse of the hematological disease after allo-HSCT remains a
challenge and is associated with poor long-term survival. Chimeric antigen receptor redirected T cells (CAR-T cells) can
lead to disease remission in patients with relapsed/refractory hematological malignancies. However, the therapeutic
window for infusion of CAR-T cells post allo-HSCT and its efficacy are debatable.
Main body: In this review, we first discuss the use of CAR-T cells for relapsed cases after allo-HSCT. We then review the
toxicities and the occurrence of graft-versus-host disease in relapsed patients who received CAR-T cells post allo-HSCT.
Finally, we review clinical trial registrations and the therapeutic time window for infusion of CAR-T cells post allo-HSCT.
Conclusions: The treatment of allogeneic CAR-T cells is beneficial for patients with relapsed B cell malignancies after
allo-HSCT with low toxicities and complications. However, multicenter clinical trials with larger sample sizes should be
performed to select the optimal therapeutic window and confirm its efficacy.
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Background
Relapse is common after allogeneic hematopoietic stem
cell transplantation (allo-HSCT) for hematological ma-
lignancy. The treatment of relapsed lymphoid malig-
nancy after allo-HSCT is challenging, as evidenced by
the low rate of remission after chemotherapy and poor
long-term survival rate [1–3]. Donor lymphocyte infu-
sion (DLI) is one of the main methods used to prevent
relapse after allo-HSCT, as it results in good outcomes;
however, the results vary for different hematological dis-
eases [4]. Donor-derived T and natural killer (NK) cells
emerge after transplantation and control leukemia,
mainly through the graft-versus-leukemia (GVL) effect.
However, DLI and donor-derived T and NK cells have
limited efficacy in preventing or treating disease relapse
after allo-HSCT and may cause life-threatening graft-
versus-host disease (GVHD), associated with infusion of
a high number of T cells in lymphoid malignancy [5–7].
Clinically significant acute GVHD develops in approxi-
mately one third of patients who receive DLI, and
GVHD is the main contributor to the 6 to 11%
treatment-related mortality rate for DLI [8]. Therefore,
new treatment strategies are needed to improve the out-
comes of higher-risk patients in the context of post-
transplantation intervention.
Chimeric antigen receptors (CARs) are fusion proteins
consisting of an antigen recognition moiety and T cell
activation domains (Fig. 1). T cells can be genetically
modified to express CARs and transfused into patients
(Fig. 2). CAR-redirected T (CAR-T) cells offer a new and
promising cell-based immunotherapy that can enhance
and effectively maintain the antitumor GVL response
after transfusion into patients without major histocom-
patibility complex restriction; treating patients with
CAR-T cells can result in the remission of refractory/re-
lapsed hematological malignancies [9–13]. Greater, more
potent patient responses have been achieved using CAR-
T cells than with therapeutic monoclonal antibodies and
related approaches [14].
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Although the use of CAR-T cells for the treatment of
refractory/relapsed hematological malignancies has been
shown to result in good outcomes, it is unclear whether
donor-derived CAR-T cells can be infused after allo-
HSCT because of the associated toxic effects and risk of
GVHD, which can lead to death [15]. In this review, we
first discuss the use of CAR-T cells to treat relapsed pa-
tients after allo-HSCT. Then, we review the occurrence
of toxicities and GVHD after allo-HSCT in relapsed
patients who were treated with CAR-T cells. Finally, we
review the clinical trial registrations and therapeutic
time window for the infusion of CAR-T cells after allo-
HSCT.
Allogeneic CAR-T cells for relapsed B cell malignancies
after allo-HSCT
Strategies for reducing the rate of relapse using CARs
rely on the use of T cells, which can be collected from
Fig. 1 Structure of a chimeric antigen receptor (CAR). The CAR comprises three parts: an ectodomain (an antigen-binding region of a monoclonal
antibody), a transmembrane domain, and an endodomain (intracellular T cell signaling domains). The lipid bilayer is an integral part of the host
cell membrane. The recognition of CAR imparts the ability of a T cell to recognize cell surface molecule; then, engagement of the CAR through
its ligand transmits a signal to the intracellular T cell signaling domain
Fig. 2 The procedure of allogeneic or autologous chimeric antigen receptor (CAR) therapy. T cells are collected from the patients or donors by
apheresis, and the T cells are then expanded and genetically modified using one of several approaches. Finally, the CAR-T cells are infused into
the patients. APCs antigen-presenting cells
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either the patient or a donor in an autologous or allo-
geneic post-HSCT setting. T cell-mediated tumor recog-
nition is known to play a pivotal role in leukemic
control. However, established leukemia cannot be com-
pletely eradicated by donor lymphocytes, often resulting
in the failure of allo-HSCT. The dual problems of a
host-versus-graft response, which would eliminate any
transferred allogeneic cells and thereby limit their per-
sistence, and a graft-versus-host response have been
encountered with the use of allogeneic CAR-T cells.
However, allogeneic CAR-T cells have been shown to
tolerize host major histocompatibility complex (MHC)
molecules in vitro prior to adoptive transfer, demonstrat-
ing that allogeneic reactivity may be reduced without
affecting the cytotoxic activity of CAR-T cells [16].
Kochenderfer et al. used donor-derived CD19-28z-
CAR-T cells to treat 10 patients (4 with chronic lympho-
cytic leukemia (CLL) and 6 with lymphoma, including 2
with diffuse large B cell lymphoma (DLBCL) and 4 with
mantle cell lymphoma (MCL)) with CD19+ B cell malig-
nancy that persisted despite allo-HSCT and at least one
standard DLI. These patients showed no GVHD, grade 1
acute GVHD, or mild global score chronic GVHD [12].
They did not receive any anti-malignancy therapy except
for CAR-T cell treatment and at least 4 weeks had
elapsed from the time of the most recent prior treatment
to the infusion of CD19-CAR-T cells. These patients
received between 0.4 × 106/kg and 7.8 × 106/kg CD19-
CAR-T cells. Within 1 month after CD19-CAR-T cell
infusion, one CLL patient achieved complete remission
(CR), 6 patients (1, 2, and 3 with CLL, DLBCL, and
MCL, respectively) had stable disease, 1 MCL patient
achieved partial remission, and two CLL patients showed
disease progression. At the last follow-up after 1 to
11 months, the same results were observed.
Cruz et al. treated 8 patients with B cell malignancy
[4 with CLL and 4 with acute lymphoblast leukemia
(ALL)] who either had disease relapse or were at high
risk of disease relapse after allo-HSCT with allogeneic
CD19-28z-CAR-T cells. Multiple salvage regimens
failed to control the relapse in 6 of these patients after
allo-HSCT, and two patients were at high risk of relapse
but were in remission at the time of CD19-CAR-T cell
infusion. None of the patients received a precondition-
ing regimen before T cell infusion. Based on total cell
numbers, CD19-CAR-T cells were administered using a
dose escalation schedule of 1.5 × 107/m2, 4.5 × 107/m2,
and 1.2 × 108/m2 [17]. Objective antitumor activity was
evident in 2 of 6 of the relapsed patients during the
period of CD19-CAR-T cell persistence, whereas 2 pa-
tients who received cells while in remission remained
disease-free. Of these 2 patients, 1 remained in CR for
more than 8 months and the other remained in CR for
8 weeks after CAR-T infusion.
Brudno et al. recently conducted a phase I dose escal-
ation trial of the use of allogeneic CD19-28z-CAR-T cells
to treat patients with B cell malignancy. These patients
(5 each with CLL, DLBCL, MCL, and ALL), except for
those with ALL or DLBCL, received at least one prior
DLI. No chemotherapy or other type of therapy was ad-
ministered. Patients with evidence of acute GVHD of
greater than grade I and those with evidence of chronic
GVHD with greater than a mild global score were ex-
cluded from this study. The patients who showed disease
progression after allo-HSCT received a single infusion of
allogeneic CD19-CAR-T cells (from 106 to 107/kg) [18].
Eight of the 20 treated patients achieved remission; six
obtained CR (4, 1, and 1 with ALL, CLL, and DLBCL,
respectively); and two achieved partial remission (1 with
MCL and 1 with CLL). The other patients had stable
disease, except for 4 patients who showed disease pro-
gression (2, 1, and 1 with CLL, ALL, and DLBCL,
respectively). The 6-month event-free survival (EFS) rate
of the 20 treated patients was 39%. The response rate
was the highest for ALL, with four of the 5 patients
achieving minimal residual disease (MRD)-negative CR.
The longest ongoing CR was more than 30 months in a
patient with CLL.
In another study, disease progression was observed
after allo-HSCT in an 11-year-old girl with relapsed ALL
who was treated with chemotherapy and DLI. Therefore,
the patient received CD19-28z-137z-27z CAR-T cell treat-
ment. After infusion of 1 × 106/kg CAR-T cells, this patient
was found to be negative for MRD. Subsequently, three
maintenance CAR-T cell infusions (0.83 × 106 − 1.65 × 106/
kg) were administered. The disease-free survival time for
this patient was 10 months [19].
Another study reported a child who relapsed after allo-
geneic cord blood transplantation and showed resistance
to multiple cytotoxic and biologic therapies, including
blinatumomab, a chimeric bispecific anti-CD3 and anti-
CD19 monoclonal antibodies. The patient received infusion
of CD19-28z CAR-T cells (1.4 × 106/kg) after chemotherapy
with etoposide and cyclophosphamide [20]. This patient
achieved MRD-negative CR at approximately 1 month
after CAR-T cell infusion but relapsed at approximately
2 months after treatment, with the loss of CD19 ex-
pression in blast cells.
Altogether, these studies suggest that allogeneic
CAR-T cells represent an effective means to treat
cases of relapse after allo-HSCT (Table 1).
Toxicities
The toxic effects of CAR-T cell treatment mainly include
cytokine release syndrome (CRS), neurotoxicity, and B
cell aplasia. CRS is the most common and potentially se-
vere toxic effect associated with this treatment [21, 22].
The development of CRS may be related to the therapeutic
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response. Patients without CRS may be less likely to bene-
fit from CAR-T cell treatment, whereas those with this
syndrome often respond to the treatment. However, stud-
ies have shown that there is no strong correlation between
the response to therapy and the severity of CRS. The
tumor burden at the time of CAR-T cell infusion may be
related to the risk of severe CRS [23]. Marked elevations
in the soluble interleukin-2 receptor alpha (sIL2Ra),
interleukin-6 (IL-6), IL-10, and interferon gamma (IFN-γ)
levels occur in CRS in an inflammatory process related to
exponential T cell proliferation, with resultant marked ele-
vations in cytokine levels [23]. The symptoms of CRS can
range from mild flu-like symptoms to multisystem organ
failure and shock, and they include marked hyperferritine-
mia (>10000 ng/mL), hepatomegaly/splenomegaly, and
hypofibrinogenemia (<150 mg/dL) [20].
Other complications of CAR-T cell therapy include
neurologic toxicities [24]. The most common toxicity is
global encephalopathy, which is brief and self-limited,
resolving over several days without intervention or ap-
parent long-term sequelae.
The toxicities of successful CAR-T cell therapy include
chronic B cell aplasia and resultant hypogammaglobuli-
nemia, which is caused by B cell aplasia/ablation and
their persistence with CAR-T cells. Thus, the late tox-
icity of B cell aplasia should be assessed in a longer
follow-up. Other toxicities associated with CAR-T cell
therapy include pneumonitis, hypotension, hypoxia,
tumor lysis syndrome, tachycardia, fatigue, fever, and
other related conditions.
The patients who received CAR-T cell infusion after
allo-HSCT in the aforementioned studies showed good
tolerance to the treatment with mild complications, in-
cluding mild-to-moderate CRS, transient hypotension,
tachycardia, and fever [12, 16–19, 23]. All of these pa-
tients fully recovered and showed complete reversal of
symptoms and normalization of laboratory results.
GVHD
GVHD is a medical complication that can occur follow-
ing allo-HSCT. It is caused by engraftment of immuno-
competent donor T lymphocytes in an immunologically
compromised host showing histocompatibility differ-
ences with the donor. These differences between the
host and donor result in donor T cell activation against
either the recipient MHC antigens or minor histocom-
patibility antigens, resulting in an excess of cytokines, in-
cluding TNF-α and IFN-γ [25, 26]. GVHD is usually
subdivided into acute GVHD and chronic GVHD. In
both child and adult patients, acute GVHD remains a
major cause of morbidity and mortality after allo-HSCT.
CRS, an inflammatory process characterized by dramatic
elevations in cytokine levels, is the most prominent and
serious toxic effect of CAR-T cell therapy. Accordingly,
CAR-T cell infusion may lead to the development of
acute GVHD after allo-HSCT. However, at present, no
cases of acute GVHD after treatment with donor-
derived CAR-T cells have been reported among relapsed
patients after allo-HSCT, and only 2 patients have devel-
oped mild chronic GVHD [12, 16–19, 23]. A possible
explanation for this lack of GVHD is the low doses of
CAR-T cells used. Another explanation may be that the
T cells were tolerized in the transplant recipient. The in-
creased anti-malignant potential of CAR-T cells allows
for the use of a small dose of T cells to eradicate malig-
nancy without causing GVHD, demonstrating a solution
to the central problem of allo-HSCT, i.e., the separation
of GVL from GVHD. Although there are few reports of










28 Between 0.4 × 106/kg
and 7.8 × 106/kg
No Fatigue, fever, and
hypotension
1 CR, 1 PR, and 6
with stable disease
Cruz et al. 8 CLL and ALL 28 Escalation schedule
of 1.5 × 107/m2,
4.5 × 107/m2, and
1.2 × 108/m2
No No 2 CR(1 remained in
CR for 8 months and
the other 1 for 8 weeks)
Brudno et al. 20 CLL, DLBCL,
MCL, and ALL





8 of 20 patients
obtained remission
(6 CR and 2 PR)
Zuo et al. 1 ALL 28, 137,
and 27
First dose 106/kg and
three maintenance
(from 0.83 × 106 to
1.65 × 106/kg)
No Mild or moderate CRS DFS for 10 months
Grupp et al. 1 ALL 28 1.4 × 106/kg No Fever MRD-negative CR at
approximately 1 month
and relapse after 2 months
CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, MCL mantle cell lymphoma, ALL acute lymphoblastic leukemia, CAR chimeric antigen
receptor, CAR-T chimeric antigen receptors redirected T cells, GVHD graft-versus-host disease, CRS cytokine release syndrome, CR complete remission, PR partial
remission, DFS disease-free survival, MRD minimal residual disease
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GVHD caused by allogeneic CAR-T cell infusion, the re-
sponses of patients appear to be inferior compared with
those achieved with autologous CAR-T cell infusion [27].
Clinical trial registrations for allogeneic CAR-T cell infusion
after allo-HSCT
Although sporadic data have shown that allogeneic
CAR-T cell infusion is safe and effective for post-
transplantation patients, evaluation of more cases and
clinical trials is necessary to further explore the role of
allogeneic CAR-T cells (Table 2).
A clinical trial (NCT01087294) was performed to as-
sess the safety and efficacy of allogeneic CD19-CAR-T
cell infusion in patients who showed no response to
allo-HSCT. The patients who received allo-HSCT were
between 18 and 75 years of age, and their diseases had
either not responded to or had recurred after the trans-
plant and at least one DLI, except for the patient with
ALL. The allogeneic CAR-T cells used were derived from
the same stem cell donor. The patients with either no
evidence of GVHD or with minimal clinical evidence of
acute or chronic GVHD received a dose escalation to
determine the most effective yet safe dose out of four
dose levels of CAR-T cells. The first patients enrolled
were treated with the smallest dose, and the dose was
increased when a level was determined to be safe. Cyclo-
phosphamide (180 mg/m2 i.v. infusion over 30 min on
days −4, −3, and −2) and pentostatin (4 mg/m2 i.v. infu-
sion over 30 min following cyclophosphamide infusion
on day −4) were administered before CAR-T cell infu-
sion. This clinical trial is now suspended.
Another clinical trial (NCT01551043) was also per-
formed to study the safety and survival of CD19-4-1BBz-
CAR-T cells in relapsed ALL patients after allo-HSCT.
Depending on their disease, patients could undergo an
additional chemotherapy treatment before the infusion
of CAR-T cells. Patients received CD19-CAR-T cells with
the dose given as a split infusion over 3 days to enhance
the ability to manage any infusion-related toxicity. Ten
subjects were targeted in this study, which has been
completed.
Presently, a clinical trial (ChiCTR-OOC-16008447) is
also underway at our center. In this study, allogeneic
CD19-CAR-T cells are being used to prevent the relapse
of B-ALL after allo-HSCT. The patients in this study
have undergone allo-HSCT and have molecular relapse,
and they were enrolled with no age limitation. The allo-
geneic CAR-T cells being used were derived from the
same stem cell donor. The patients with early molecular
relapse have received one dose of CAR-T cells (1 × 106/
kg). These patients may undergo one or two additional
CAR-T cell infusions at the same dose according to their
disease status. No chemotherapy was administered be-
fore CAR-T cell infusion. The main endpoint is the one-
year disease-free survival rate.
Therapeutic time window for allogeneic CAR-T cell infu-
sion after allo-HSCT
Allogeneic CAR-T cells undergo dramatic expansion,
followed by their eventual clearance, and they provide a
similar benefit as syngeneic CAR-T cells. Despite the
dramatic expansion of allogeneic CAR-T cells, the re-
ported GVHD manifestations have been very mild and
have been limited to transient weight loss with no
GVHD-related mortality [28]. These findings suggest
that allogeneic CAR-T cells can be used to treat or pre-
vent relapse after allo-HSCT. However, the therapeutic
time window for CAR-T cell infusion after allo-HSCT
remains to be determined.
There is no standard time point for CAR-T cell infu-
sion after allo-HSCT. The current data indicate that all
patients who have received CAR-T cell treatment were
refractory to or relapsed after allo-HSCT, and all of these
patients received chemotherapy or DLI. Preemptive
treatment with allogeneic CAR-T cells upon the early de-
tection of leukemic relapse following HSCT by stringent
monitoring of MRD has also been performed in some
cases [17]. In our clinical trial (ChiCTR-OOC-160
08447), preemptive treatment with allogeneic CAR-T
Table 2 Clinical trial registrations on allogeneic CAR-T cell infusion after allo-HSCT in B cell malignancies










Either did not respond
to or recurred after
allogeneic transplantation
Not shown Cy 180 mg/m2 for
3 days and pentostatin


















B-ALL Molecular relapse after
allogeneic transplantation
Not shown No 1 × 106/kg II Recruiting ChiCTR-OOC-
16008447
Note: The trials are registered at ClinicalTrials.gov and http://www.chictr.org.cn/index.aspx. Search was performed on December 18, 2016.
CAR-T chimeric antigen receptors redirected T cells, allo-HSCT allogeneic stem cell transplantation, Cy cyclophosphamide, B-ALL B cell acute
lymphoblastic leukemia
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cells upon early detection of molecular relapse of B-ALL
was performed.
Identification of the risk factors for and timing of re-
lapse after allogeneic HSCT might enable development
of an important prognostic tool for use in patients with
lymphoid malignancy requiring CAR-T cell treatment
[15, 29]. The period between days +55 and +200 after
HSCT has been reported to be the optimal time window
for early immune intervention aimed at preventing re-
lapse, according to the identification of patients at high
risk of relapse after transplantation, the presence of
MRD pre-HSCT or post-HSCT, and the occurrence of
GVHD. Thus, preemptive treatment with allogeneic
CAR-T cells might also be performed to reduce relapse
and to improve long-term survival after allo-HSCT in
high-risk patients with lymphoid malignancy, but further
study is needed.
Conclusions
Preventing and treating relapsed disease remains an un-
met clinical need after allo-HSCT in B cell malignancies.
Some diseases have been successfully treated with allo-
geneic CAR-T cells without serious complications after
allo-HSCT; however, the outcome requires further im-
provement. As the efficacy of cell therapies is related to
the low tumor burden, preemptive therapy should be
performed upon the detection of MRD via molecular or
immunophenotypic methods [30]. Therefore, the allo-
geneic CAR-T cell treatment should be standardized for
patients with allo-HSCT. The best time for CAR-T cell
infusion is between days +55 and +200 after allo-HSCT.
Thus, the infusion of CAR-T cells performed immedi-
ately or following MRD-positive relapse after allo-HSCT
may be the best model because of the limited effect after
hematological relapse. Cell therapies should be inte-
grated into routine practice and considered the standard
of care. However, the identification of unique tumor an-
tigens that can be targeted with selective T cell therapies
is a major challenge.
Why CAR-T cells can attack malignant blasts in some
cases but remain paralyzed in others remains unknown.
The effects of CAR-T cells are pivotal for the loss of co-
stimulatory molecules and the expression of co-inhibitory
molecules in tumor immune escape. Sustained inhibitory
signaling on T cells by molecules such as TIM-3, LAG-3,
PD-1, and CTLA-4 correlates with a stage of T cell ex-
haustion marked by reduced T cell proliferative potential,
effector function, and cytotoxicity [31]. The increase of
immune checkpoint proteins expressed in B cell malig-
nancies can lead to resistance to blinatumomab, a bispeci-
fic T cell engager monoclonal antibody (CD19/CD3) or
CAR-T cells [32]. On the other hand, the use of immune
checkpoint inhibitors can improve the complete responses
of B cell malignancies [33]. Thus, it is important to
achieve sustained tumor immune surveillance and effi-
cient elimination of malignant cells by increasing T cell
function and reversing T cell exhaustion. Further identifi-
cation of biomarkers for CAR-T infusion to improve the
outcome is therefore required.
The central questions surrounding CAR-T cell treat-
ment, namely whether they have toxic effects and
whether CAR-T cells are sustainable, have hindered its
broad clinical application. The choice of effector T cells
and the design of CARs must be optimized to improve
the effectiveness and limit toxicities [34, 35]. In addition,
novel allogeneic procedures aimed at optimizing feasibil-
ity and clinical efficacy without significantly increasing
the risks of toxicities, and GVHD should also be further
explored. A recent study found that the chimeric forms
of Notch can serve as a general platform for generating
novel cell-cell contact signaling pathways. Multiple syn-
Notch receptors can be used in the same cell to achieve
a combinatorial integration of environmental cues. Thus,
SynNotch receptors provide extraordinary flexibility in
engineering cells with customized sensing/response be-
haviors to user-specified extracellular cues [36]. Another
study showed that CAR-T cells constructed with a syn-
thetic Notch receptor are only armed and activated in
the presence of dual antigen tumor cells. Therefore,
these T cells show precise therapeutic discrimination in
vivo, sparing single antigen “bystander” tumors while ef-
ficiently clearing combinatorial antigen “disease” tumors
[37]. The CAR-T cell dose must be optimized to obtain
the maximum effect with the lowest risks of toxicities
and GVHD; however, the standard dose of CAR-T cells
requires further exploration.
There are many ways to prevent or treat the relapse of
B cell malignancies after allo-HSCT; of these, DLI is the
most commonly used. However, the responses to DLI
are poor, with high rates of GVHD and non-relapse
mortality occurrence for B cell malignancies [5, 38]. Bli-
natumomab is used to manage relapsed/refractory Ph+
ALL and may be used to treat patients with relapse after
allo-HSCT [39]. A patient with Pre-B-ALL relapse who
displayed a loss of donor chimerism to 43% and no evi-
dence of GVHD was treated with blinatumomab. The
patient achieved remission and remains in remission at
240 days post-transplant with 100% donor chimerism
[40]. Three pediatric patients with B-precursor ALL re-
lapse following allo-HSCT received blinatumomab, and
rapid MRD-negative CR was achieved without the oc-
currence of GVHD [41]. Another report showed no re-
sponse for blinatumomab but that CAR-T cells were
effective [20]. Presently, the number of cases in which
blinatumomab is used in the treatment of relapsed B cell
malignancies after allo-HSCT is small; thus, further
study is required [42]. Interestingly, CAR-T can pene-
trate the blood-brain barrier [43], whereas whether
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blinatumomab can do so remains unclear. The optimal
treatment duration and schedule of blinatumomab for
patients with relapse after allo-HSCT is not known.
Altogether, compared to the current methods used to
prevent or treat relapse after allo-HSCT, allogeneic
CAR-T cell therapy is a safer and more feasible ap-
proach; however, multicenter clinical trials with larger
sample sizes should be performed.
In conclusion, allogeneic CAR-T cells represent an ex-
tremely promising tool for the prevention or treatment
of relapsed B cell malignancies after allo-HSCT. How-
ever, relevant studies are at an early stage, and many
crucial questions remain to be answered, such as the
mechanism for relapse after CAR-T infusion.
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